US EditionPublished • loading... • Updated
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche's $3.5 billion acquisition of 89bio includes milestone-based payments tied to pegozafermin's commercial sales, targeting treatment for moderate to severe metabolic dysfunction-associated steatohepatitis.
- On September 17, 2025, Roche announced a merger agreement to acquire 89bio, Inc. for $14.50 per share cash, with stockholders receiving up to $20.50 including a non-tradeable CVR, valuing the deal at $3.5 billion; Roche said 89bio will join its Pharmaceuticals Division.
- Roche said the acquisition will bolster its cardiovascular, renal, and metabolic diseases portfolio and pegozafermin, 89bio's phase 3 candidate, targets moderate to severe Metabolic Dysfunction-Associated Steatohepatitis .
- The company said the Board unanimously approved the merger and an affiliate of Roche will commence a tender offer with a $2.4 billion aggregate payment; 89bio is headquartered in San Francisco.
- Roche's Boris L. Za�tra said, `We are excited about this agreement and to further develop this promising therapy, which we hope will provide people with moderate to severe MASH a new treatment option`, with the deal expected to close in the fourth quarter of 2025, subject to risks and conditions.
- The agreement includes non-tradeable contingent value rights offering milestone payments of $2.00, $1.50, and $2.50 per share by March 31, 2030; December 31, 2033; and December 31, 2035, tying value to pegozafermin's commercial success and encouraging long-term incentives.
Insights by Ground AI
24 Articles
24 Articles
The Swiss pharmaceutical giant goes deep into his pocket: what is behind the billions purchase of 89bio – and why is an American drug candidate considered a hope for liver disease?
Roche to Buy Biopharmceutical Firm 89bio in $3.5 Billion Deal
Roche Holding AG said it will acquire biopharmaceutical company 89bio, Inc. in a deal valued at $3.5 billion, bolstering the Swiss pharmaceutical giant’s pipeline of cardiovascular, renal, and metabolic disease treatments.
·United States
Read Full ArticleCoverage Details
Total News Sources24
Leaning Left2Leaning Right0Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 22%
C 78%
Factuality
To view factuality data please Upgrade to Premium
